Federal law bars Medicare from covering drugs used for weight loss, but Medicare does cover the same medications for diabetes or heart disease. Since July 2026 a temporary CMS demonstration, the Medicare GLP-1 Bridge, has let eligible beneficiaries get certain GLP-1s for about $50 a month. The exclusion itself is still on the books.
Why Medicare doesn't cover GLP-1s for weight loss
Since 2003, federal law has excluded "agents used for weight loss" from Medicare Part D coverage. The rule was written long before GLP-1 medications existed and was aimed at older weight-loss drugs. The result today: Medicare can cover semaglutide or tirzepatide when it's prescribed for type 2 diabetes, and in some cases for an FDA-approved cardiovascular risk-reduction indication, but not when it's prescribed for obesity or weight management. It can be the same drug, at the same dose, for the same patient.
The Medicare GLP-1 Bridge: a temporary program
In 2026, CMS launched the Medicare GLP-1 Bridge, a temporary demonstration that gives eligible beneficiaries access to certain GLP-1 obesity medications without Congress changing the weight-loss exclusion. The details, as of September 2026:
- What it costs: you pay about $50 for each 30-day supply. Manufacturers have agreed to a net price of about $245 a month for Bridge prescriptions, and Medicare pays the rest of that discounted price. In practice the pharmacy is reimbursed at roughly the list price minus your copay, and the manufacturer then pays CMS back the difference between list price and $245.
- When it runs: it began July 1, 2026 and is set to continue through December 31, 2027. On April 21, 2026, CMS said it would not start the broader BALANCE Model in Medicare in 2027 and extended the Bridge through the end of 2027 instead.
- Which drugs: CMS lists Foundayo, Wegovy (injection and tablets) and the KwikPen form of Zepbound (Zepbound vials and single-dose pens are excluded). Foundayo is the brand name for orforglipron, Lilly's once-daily GLP-1 pill, which the FDA approved on April 1, 2026. The list can change, so check current CMS guidance.
- Who qualifies: tiered BMI criteria. A BMI ≥ 35 qualifies on its own. A lower BMI qualifies with a specific related condition: BMI ≥ 30 with heart failure, uncontrolled hypertension, or kidney disease; or BMI ≥ 27 with a previous stroke or heart attack, prediabetes, or peripheral artery disease. You also need to be enrolled in Part D or Medicare Advantage and have prior authorization from your prescriber. Your prescriber or plan can confirm whether you meet the rules.
- How it works: the Bridge runs outside the normal Part D benefit and payment flow. CMS is using Humana, which already runs the LI NET program, as the central processor, and Part D plans don't have to opt in for their members to get access.
The Bridge is a demonstration, not a permanent benefit. It has an end date, it covers less than full coverage would, and it doesn't repeal the 2003 exclusion. That's why advocates still treat legislative and administrative reform as the long-term goal. The dates have already shifted once, so check current, dated CMS sources before you rely on them.
What else is being proposed to change this
The "Treat and Reduce Obesity Act" has been reintroduced across multiple sessions of Congress without passing. CMS has also explored administrative routes, including the BALANCE Model, a proposal to let Part D plans cover anti-obesity medications more broadly; its Medicare component was delayed rather than launched on its original timeline. Policy here moves slowly and has shifted between administrations, so re-check the status against current sources.
Why this fight matters beyond Medicare enrollees
Advocates argue that Medicare coverage decisions influence the wider insurance market, because private insurers and PBMs often look to Medicare when setting their own coverage. On that view, ending the Medicare exclusion would also shift coverage norms in commercial insurance, not only help Medicare beneficiaries.
How patients and advocates are pushing for change
- Public comment periods: CMS and Congress periodically open public comment on related rules. It's a direct, low-effort way to get your input on the record.
- Contacting congressional representatives: bills like the Treat and Reduce Obesity Act move (or stall) partly on visible constituent interest.
- Supporting patient advocacy organizations that lobby on obesity policy (see our guide on the role of patient advocacy organizations). These groups often run campaigns timed to legislative sessions.
- Sharing your story with lawmakers and the media. A specific account of how coverage affects you gives a policymaker something that aggregate statistics don't.
The exclusion predates today's GLP-1 medications, and the Bridge gets some people low-cost access now. Whether the rule changes for good depends on Congress or CMS acting before the Bridge ends, and you can add your voice even if you're not on Medicare yet.
This article is general education, not medical, legal, or insurance advice. Program dates, eligibility, and drug lists for the Medicare GLP-1 Bridge can change. Confirm the current details with CMS, your Part D plan, or your prescriber before acting.